Connect
MJA
MJA

2. Anaphylaxis: diagnosis and management

Simon G A Brown, Raymond J Mullins and Michael S Gold
Med J Aust 2006; 185 (5): 283-289.
  • Simon G A Brown1
  • Raymond J Mullins2
  • Michael S Gold3

  • 1 University of Western Australia and Fremantle Hospital, Fremantle, WA.
  • 2 Australian National University, Canberra, ACT.
  • 3 Women’s and Children’s Hospital and University of Adelaide, Adelaide, SA.

Correspondence: simon.brown@uwa.edu.au

Acknowledgements: 

The authors are grateful for the many helpful comments by Dr Bob Heddle.

Competing interests:

None identified.

  • 1. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report — second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117: 391-397.
  • 2. Mullins RJ. Anaphylaxis: risk factors for recurrence. Clin Exp Allergy 2003; 33: 1033-1040.
  • 3. Peng MM, Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch Intern Med 2004; 164: 317-319.
  • 4. Yocum MW, Butterfield JH, Klein JS, et al. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol 1999; 104: 452-456.
  • 5. Boros CA, Kay D, Gold MS. Parent reported allergy and anaphylaxis in 4173 South Australian children. J Paediatr Child Health 2000; 36: 36-40.
  • 6. Brown SGA, Franks RW, Baldo BA, Heddle RJ. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J Allergy Clin Immunol 2003; 111: 187-192.
  • 7. Moneret-Vautrin DA, Morisset M, Flabbee J, et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005; 60: 443-451.
  • 8. Brown AF, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108: 861-866.
  • 9. Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371-376.
  • 10. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne schoolchildren: have we reached the peak? Med J Aust 2004; 180: 273-276. <MJA full text>
  • 11. Sheikh A, Alves B. Hospital admissions for acute anaphylaxis: time trend study. BMJ 2000; 320: 1441.
  • 12. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82: 233-248; quiz 248-252.
  • 13. Braganza SC, Acworth JP, McKinnon DR, et al. Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child 2006; 91: 159-163.
  • 14. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30: 1144-1150.
  • 15. Ring J, Brockow K, Behrendt H. History and classification of anaphylaxis. Novartis Found Symp 2004; 257: 6-16; discussion 16-24, 45-50, 276-285.
  • 16. Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 2000; 105: 847-859.
  • 17. Brown SGA. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas 2006; 18: 155-169.
  • 18. Brown SGA, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004; 21: 149-154.
  • 19. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4: 285-290.
  • 20. Australasian Society of Clinical Immunology and Allergy Anaphylaxis Working Party. Guidelines for EpiPen prescription. Sydney: ASCIA, 2004. http://www.allergy.org.au/anaphylaxis/epipen_guidelines.htm (accessed Feb 2006).
  • 21. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108: 871-873.
  • 22. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101 (1 Pt 1): 33-37.
  • 23. Brown SGA, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361: 1001-1006.
  • 24. Oude Elberink JN, De Monchy JG, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110: 174-182.
  • 25. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Canberra: NHMRC, 2000. http://www.nhmrc.gov.au/publications/_files/cp69.pdf (accessed Jul 2006).
  • 26. Heytman M, Rainbird A. Use of alpha-agonists for management of anaphylaxis occurring under anaesthesia: case studies and review. Anaesthesia 2004; 59: 1210-1215.
  • 27. Schummer W, Schummer C, Wippermann J, Fuchs J. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology 2004; 101: 1025-1027.
  • 28. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Two case reports. Int Arch Allergy Immunol 2004; 134: 260-261.
  • 29. Zaloga GP, DeLacey W, Holmboe E, Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med 1986; 105: 65-66.
  • 30. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22: 272-273.
  • 31. Brown SGA. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5: 359-364.
  • 32. Brown SGA, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas 2004; 16: 120-124.
  • 33. Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78 (1 Pt 1): 76-83.
  • 34. Mullins RJ, Heddle RJ, Smith P. Non-conventional approaches to allergy testing: reconciling patient autonomy with medical practitioners’ concerns [editorial]. Med J Aust 2005; 183: 173-174. <MJA full text>
  • 35. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348: 986-993.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.